The Human Gut-Liver-Axis In Health And Disease
A. Krag, T. Hansen
Published 2019 ·
Download PDFAnalyze on Scholarcy
This paper references
Incidence, etiology and mortality of cirrhosis: a population-based cohort study
A. D. Fialla (2012)
The effect of acute
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop
A. Sanyal (2015)
Evolution of non - invasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C
J Vergniol (2014)
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.
M. Karsdal (2015)
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
Asociacion Latinoamericana para el Estudio del Higado (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
B. A. Neuschwander-Tetri (2015)
Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.
Emily Cohen (2007)
Alcoholic liver disease: mechanisms of injury and targeted treatment
A. Louvet (2015)
The effect of acute alcohol intoxication on gut wall integrity in healthy male volunteers; a randomized controlled trial.
Wilfried de Jong (2015)
The Utility of Commonly Used Laboratory Tests to Screen for Excessive Alcohol Use in Clinical Practice.
Gina Gough (2015)
Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations
S. van Katwyk (2017)
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
R. Kwok (2015)
Colonic microbiome is altered in alcoholism.
E. Mutlu (2012)
Clinical course of alcoholic liver cirrhosis: A Danish population‐based cohort study
P. Jepsen (2010)
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
F. Ponziani (2016)
Non-invasive diagnosis of hepatic steatosis
C. Stern (2016)
Gut microbiome and liver diseases
H. Tilg (2016)
Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis.
M. Thiele (2016)
Causes of Death in People with Liver Cirrhosis in England Compared with the General Population: A Population-Based Cohort Study
S. Ratib (2015)
Global burden of alcoholic liver diseases.
J. Rehm (2013)
Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar
M. A. Karsdal (2014)
Dietary saturated lipids in alcoholic liver disease: new microbiota-targeting bullets?
Herbert Tilg (2015)
Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta‐analysis
Y. Xie (2014)
Histopathology of alcoholic liver disease
N. Theise (2013)
Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.
E. Stein (2016)
The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.
A. Palmer (2000)
Gut-liver axis in alcoholic liver disease.
G. Szabo (2015)
Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C
J. Vergniol (2014)
Alcohol dependence and risk of somatic diseases and mortality: a cohort study in 19 002 men and women attending alcohol treatment
C. Holst (2017)
The relationship between different dimensions of alcohol use and the burden of disease—an update
J. Rehm (2017)
Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
Edith M. Koehler (2016)
Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.
John Guirguis (2015)
Acute Binge Drinking Increases Serum Endotoxin and Bacterial DNA Levels in Healthy Individuals
S. Bala (2014)
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
C. Ripoll (2007)
Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease
M. Llopis (2015)
Liver disease in the UK: a Lancet Commission
R. Williams (2013)
Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients
M. Soto (2017)
Cirrhosis improvement to alcoholic liver fibrosis after passive abstinence
H. Takahashi (2014)
Evaluation of work-based screening for early signs of alcohol-related liver disease in hazardous and harmful drinkers: the PrevAIL study
Penny A Cook (2015)
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.
R. de Franchis (2015)
Transient Elastography for Diagnosis of Stages of Hepatic Fibrosis and Cirrhosis in People with Alcoholic Liver Disease
C. Pavlov (2017)
Hepatic steatosis: Innocent bystander or guilty party?
C. Day (1998)
Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.
C. Lieber (2004)
Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis.
J. Rehm (2010)
Cirrhosis and mortality risks of biopsy‐verified alcoholic pure steatosis and steatohepatitis: a nationwide registry‐based study
T. Deleuran (2012)
D. Schuppan (2008)
The genetics of alcohol dependence and alcohol-related liver disease.
F. Stickel (2017)
Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study.
T. Sandahl (2011)
Gut Microbiota, Cirrhosis, and Alcohol Regulate Bile Acid Metabolism in the Gut
J. Ridlon (2015)
Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.
N. Sheron (2016)
Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia
L. Xue (2017)
Targeting the gut-liver axis in liver disease.
R. Wiest (2017)
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
S. Bluemel (2016)
Rates and predictors of relapse after natural and treated remission from alcohol use disorders.
R. Moos (2006)
Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study
M. Y. Kim (2012)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
M. Armstrong (2016)
Decompensated alcohol related liver disease: acute management
S. McPherson (2016)
Critical comparison of elastography methods to assess chronic liver disease
M. Friedrich-Rust (2016)
The clinical use of HVPG measurements in chronic liver disease
J. Bosch (2009)
Five‐year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence
F. Pessione (2003)
microbiome and liver diseases
Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients.
E. Gelsi (2011)
Effect of policy, economics, and the changing alcohol marketplace on alcohol related deaths in England and Wales
N. Sheron (2016)
Drinking habits as cofactors of risk for alcohol induced liver damage
S. Bellentani (1997)
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
D. Jonas (2014)
Inflammasome activation and function in liver disease
G. Szabo (2015)
Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.
C. Lackner (2017)
Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study.
G. Askgaard (2015)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
D. Kleiner (2005)
Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients
G. D'Amico (2014)
Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies
C. Hart (2010)
Intestinal fungi contribute to development of alcoholic liver disease
An-Ming Yang (2017)
Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
J. Bajaj (2013)